Univercells S.A.
Univercells is a biotech-focused holding company dedicated to transforming biomanufacturing and increasing access to biologics worldwide. Through innovation, strategic partnerships, and cutting-edge technologies, it supports the development, manufacturing, and distribution of vaccines, biologics, and gene therapies. The company collaborates with global health organizations, academic institutions, and industry leaders to accelerate the availability of life-saving treatments and advance biopharmaceutical manufacturing capabilities.
Industries
Nr. of Employees
large (251-1000)
Univercells S.A.
Avenue Centrale 52, Zoning de Jumet, 6040 Charleroi, Belgium
Products
Continuous RNA production platform
A continuous manufacturing platform for mRNA and saRNA that integrates continuous flow production with upstream/downstream modules and analytics to increase throughput and support rapid scale‑up from sequence design to larger‑scale production.
Integrated viral vector production platform
A modular production platform combining upstream, downstream and analytical modules to accelerate deployment of viral vector manufacturing processes and reduce operational complexity.
Continuous RNA production platform
A continuous manufacturing platform for mRNA and saRNA that integrates continuous flow production with upstream/downstream modules and analytics to increase throughput and support rapid scale‑up from sequence design to larger‑scale production.
Integrated viral vector production platform
A modular production platform combining upstream, downstream and analytical modules to accelerate deployment of viral vector manufacturing processes and reduce operational complexity.
Services
Contract development and GMP manufacturing for viral vectors and nucleic acid therapeutics, from early development through clinical and commercial production.
Analytical method development, validation, and routine QC testing for RNA and viral vector products, including quantitative molecular assays (ddPCR), ELISA, stability and release testing, sample management and Certificate of Analysis reporting.
Hands‑on support for transferring processes from development to GMP, including engineering runs, transfer documentation, batch records and on‑site implementation to de‑risk scale‑up.
Design and delivery of biomanufacturing training curricula and partnership programs with training centers and academic institutions to upskill local manufacturing teams and operators.
Contract development and GMP manufacturing for viral vectors and nucleic acid therapeutics, from early development through clinical and commercial production.
Analytical method development, validation, and routine QC testing for RNA and viral vector products, including quantitative molecular assays (ddPCR), ELISA, stability and release testing, sample management and Certificate of Analysis reporting.
Hands‑on support for transferring processes from development to GMP, including engineering runs, transfer documentation, batch records and on‑site implementation to de‑risk scale‑up.
Design and delivery of biomanufacturing training curricula and partnership programs with training centers and academic institutions to upskill local manufacturing teams and operators.
Expertise Areas
- Bioprocessing and scale‑up
- Viral vector manufacturing (AAV and other vectors)
- mRNA and saRNA continuous manufacturing
- CDMO development and technology transfer
Key Technologies
- Continuous RNA manufacturing
- Fixed‑bed bioreactors
- Single‑use systems
- Bioreactor operations (adherent and suspension)
News & Updates
MoU signed between Bio-Manguinhos/Fiocruz, Quantoom Biosciences, and Univercells during the Belgian Economic Mission to Brazil to develop RNA-based vaccines and therapies.
EIB boosts Univercells with €30 million to support COVID-19 related projects, including vaccine manufacturing facilities in Belgium.
Discusses the role of mRNA technology transfer programs in democratizing vaccine development and production.
MoU signed between Bio-Manguinhos/Fiocruz, Quantoom Biosciences, and Univercells during the Belgian Economic Mission to Brazil to develop RNA-based vaccines and therapies.
EIB boosts Univercells with €30 million to support COVID-19 related projects, including vaccine manufacturing facilities in Belgium.
Discusses the role of mRNA technology transfer programs in democratizing vaccine development and production.